The biopharma industry has changed significantly during the past 10 years, and so has Life Science Leader. What will the next decade have in store for issues such as drug pricing and new therapeutic advances?
When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.
When Baxter spun off its biotechnology operations into an independent entity named Baxalta, its management team began executing a successful culture change with a unique self-enrollment model. This is the story of how that self-enrollment model worked.
As Congress grapples with complex ways to provide greater care coordination for seniors with multiple chronic conditions and value-based reimbursement schemes for prescription drugs, an obvious solution is being fundamentally ignored: greater enrollment in Medicare Advantage (MA).
Gene and cell therapy research has progressed despite the considerable challenges that require new approaches to the standard drug-development process and timeline. Here are some alternate development and financing models to consider.
Ameet Nathwani, M.D., EVP of Sanofi’s medical function, discusses digital health joint venture with Verily Life Sciences, and good places to look for digital health top talent.
In this preview of our July 2018 issue, the CEO of Sage Therapeutics, Jeff Jonas, M.D., elaborates on the company’s approach to developing small clinical trials.
Sage Therapeutics’ CEO Jeff Jonas, M.D., discusses what he means by a “return to the basics of science” at his company.
When preparing for product commercialization, biotechs need to assess internal capacity and capabilities with the following goals in mind:
Multinational pharmaceutical companies have for decades manufactured drugs for global distribution. Nevertheless, the task of labeling is becoming increasingly difficult and time-consuming.
Latin America is developing into a sizable, predictable part of the global medical device market, allowing foreign manufacturers to have sustainable commercial operations.
A look at the role real-world evidence (RWE) can play in increasing the uptake of biosimilars in the U.S. market and some of the challenges in leveraging the potential of RWE.
While the Theranos scandal was a disappointment, recent studies in liquid biopsies demonstrate that real, capital-efficient innovation is alive and well.
There are some easy ways to improve communication on your clinical trial. But before we get into that, let’s consider how poor communication can derail your clinical trial.
A look at ANDA litigations and the necessity of understanding where the “act of infringement” has occurred to determine if venue is proper in pharmaceutical litigation.
The passing of the Right to Try Act came after years of debate among politicians, the pharmaceutical industry, and other stakeholders about the potential legal, ethical, regulatory, and business impacts of RTT. That debate is unlikely to end any time soon.